Cytotoxicity of Platinum and Palladium Chelates against Osteosarcoma

abstract

This work reports the half maximal inhibitory concentrations, IC50, for conventional anti-cancer drug oxaliplatin (OXA) and potential new drugs Pt(2)Cl(2)Spm (Pt(2)Spm) and Pd(2)Cl(2)Spm (Pd(2)Spm) (Spm=Spermine) against osteosarcoma (OS). IC50 values provided by the (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and Alamar Blue (AB) viability assays and cell density Sulforhodamine B (SRB) test were compared. Values obtained with MTT and AB were generally in agreement, and a tendency for lower IC50 values was noted by SRB, for OXA and Pd(2)Spm. The relative suitability of different assays is discussed for each chelate. The IC50 trend: cisplatin (cDDP)approximate to Pd(2)Spm

keywords

CISPLATIN RESISTANCE; BIOGENIC POLYAMINES; METAL-COMPLEXES; CELLS; PATHWAY; DRUGS; APOPTOSIS; IMPACT; NMR

subject category

Chemistry

authors

Martins, AS; de Carvalho, ALMB; Lamego, I; Marques, PM; Gil, AM

our authors

Share this project:

Related Publications

We use cookies for marketing activities and to offer you a better experience. By clicking “Accept Cookies” you agree with our cookie policy. Read about how we use cookies by clicking "Privacy and Cookie Policy".